Back to Search
Start Over
The roles of M30 and M65 in the assessment of treatment response and prognosis in patients with non-small cell lung cancer, who receive neoadjuvant treatment
- Source :
- Contemporary Oncology, Contemporary Oncology, Vol 23, Iss 4, Pp 208-213 (2019)
- Publication Year :
- 2019
- Publisher :
- Termedia Publishing House, 2019.
-
Abstract
- Aim of the study To investigate the efficacy of evaluating prognosis and response to lung cancer treatment using M30 and M65 antigens, which are indicators of necrosis. Material and methods Forty-eightpatients with lung cancer, who were planned to receive neoadjuvant chemotherapy, and 38 healthy volunteers were enrolled in the study. Using M30 and M65 levels, cytokeratin 18 levels were measured twice: before and 48 hours after the first chemotherapy treatment. Apoptotic and total necrosis levels were determined by measuring the M65 and M30 levels. Results The M30 and M65 antigen levels in the patient group were significantly higher than in the control group (p< 0.001). The M30 and M65 antigen levels were significantly higher 48 hours after the chemotherapy compared with before the chemotherapy (p< 0.001). There were no significant differences in M65 levels between patients who responded to treatment and patients who progressed. The M30 levels increased significantly in patients with disease progression (p= 0.694 and p = 0.024, respectively). No significant differences in serum M30 and M65 antigen levels were found when compared between the surviving and deceased patients (p = 0.126 and p = 0.340, respectively). Conclusions A significant increase was detected in serum M30 and M65 levels in patients with lung cancer. There was a greater increase in serum M30 levels in patients who did not respond to the chemotherapy. This result gives rise to the thought that evaluating apoptosis and total necrosis through M30 and M65 measurements alone only in patients receiving neoadjuvant chemotherapy would be insufficient for specifying the effectiveness of the treatment.
- Subjects :
- 0301 basic medicine
neoadjuvant treatment
medicine.medical_specialty
Necrosis
medicine.medical_treatment
lcsh:Medicine
Gastroenterology
03 medical and health sciences
Cytokeratin
0302 clinical medicine
Antigen
Internal medicine
medicine
Radiology, Nuclear Medicine and imaging
In patient
Lung cancer
Chemotherapy
Original Paper
030102 biochemistry & molecular biology
business.industry
lcsh:R
medicine.disease
lung cancer
Oncology
Apoptosis
030220 oncology & carcinogenesis
prognosis
medicine.symptom
business
cytokeratin
M65-Antigen
Subjects
Details
- Language :
- English
- ISSN :
- 18974309 and 14282526
- Volume :
- 23
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Contemporary Oncology
- Accession number :
- edsair.doi.dedup.....b7d083bc38c60999c57f0da3c71779d3